SCHEMBL2893564

SCHEMBL2893564

CN1CCN(C(=O)c2ccc(-c3ccc(CN4CC(c5ccccc5)OC4=O)cc3)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
CHKA P35790 1/20 0.51
GRM2 Q14416 2/20 0.50
HRH3 Q9Y5N1 2/20 0.48
FADS1 O60427 1/20 0.46
LTB4R2 Q9NPC1 1/20 0.46
CYP2C9 P11712 1/20 0.44
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
NPC1 O15118 1/20 0.44
GRM5 P41594 1/20 0.44
TNKS O95271 1/20 0.43
FABP6 P51161 1/20 0.43
LMNA P02545 4/20 0.42
TSHR P16473 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2893568 1.00 POLB (0.55) POLBCHKAGRM2HRH3FADS1
SCHEMBL2900150 0.92 GRM2 (0.48) POLBCHKAGRM2FADS1LMNA
SCHEMBL2900149 0.92 GRM2 (0.48) POLBCHKAGRM2FADS1LMNA
SCHEMBL13086078 0.85 GRM2 (0.56) CHKAGRM2FADS1
SCHEMBL2893311 0.85 GRM2 (0.56) CHKAGRM2FADS1
SCHEMBL2899170 0.84 GRM2 (0.56) GRM2FADS1
SCHEMBL2896844 0.84 GRM2 (0.56) GRM2FADS1
SCHEMBL2894128 0.84 GRM2 (0.50) GRM2FADS1
SCHEMBL4325271 0.82 MC4R (0.52) CHKAGRM2FADS1NPC1LMNA
SCHEMBL4325275 0.82 MC4R (0.52) CHKAGRM2FADS1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US claimed
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US claimed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US claimed
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US disclosed
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US disclosed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM2 POLB 3048/4885CHKA 2467/4885GRM2 3/4885
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 POLB 3048/4885CHKA 2467/4885GRM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.